Address: Av. Prof. Vicente Rao, 90 Brooklin – São Paulo-SP,Brazil
Tel: +55 11 5532 7122
Web: http://www.novartis.com.br/
Novartis provides healthcare solutions that address the changing needs of patients and the public. Focused solely on healthcare, the company offers a diversified portfolio to best meet these needs: innovative medicines and generics, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in all these areas. In 2010, the Group achieved net sales of $ 50.6 billion, while about $ 9.1 billion was invested in research and development across the Group. Headquartered in Basel, Switzerland, the Novartis Group of companies employ approximately 119,000 people (including 16,700 from Alcon) and operate in approximately 140 countries around the world.
In Brazil, Novartis has consolidated its position as the number one research-based pharmaceutical company. Novartis is the only global company producing APIs in Brazil, which is one of the key health industrial policy objectives of the Brazilian government, and is the only global pharmaceutical company building a new biotech factory.
Diovan
Bravo (valsartan)
Brav HCT (valsartan HCT)
Bramlea (valsartan, amlodipine).
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with the regulatory picture. In…
Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to sell pharmaceuticals, or the…
Many readers may find it counterintuitive that SINDUSFARMA, which represents syndicates, is organized by a team of management executives. Historically, these two groups tend to be in opposition. Can you…
What would you recommend in terms of increasing the competitiveness and growth of the Brazilian pharmaceutical industry? The Brazilian pharmaceutical industry needs to improve its R&D capabilities. I personally think…
We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a…
Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
See our Cookie Privacy Policy Here
